BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 26529014)

  • 1. Acupoint injection of onabotulinumtoxin A for migraines.
    Hou M; Xie JF; Kong XP; Zhang Y; Shao YF; Wang C; Ren WT; Cui GF; Xin L; Hou YP
    Toxins (Basel); 2015 Oct; 7(11):4442-54. PubMed ID: 26529014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis.
    Elkind AH; O'Carroll P; Blumenfeld A; DeGryse R; Dimitrova R;
    J Pain; 2006 Oct; 7(10):688-96. PubMed ID: 17018329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type a therapy in migraine: preclinical and clinical trials.
    Shao YF; Zhang Y; Zhao P; Yan WJ; Kong XP; Fan LL; Hou YP
    Iran Red Crescent Med J; 2013 Oct; 15(10):e7704. PubMed ID: 24693369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onabotulinumtoxin Type A reconstitution with preserved versus preservative-free saline in chronic migraine (B-RECON). A randomised, double-blind trial.
    Zidan A; Hussaini S; Gibson S; Brooks G; Mejico L
    Int J Clin Pract; 2020 Sep; 74(9):e13522. PubMed ID: 32350975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S; Mathew N; Saper J; Jenkins S
    Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
    Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
    Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Stark SR; Lucas SM; Christie SN; Degryse RE; Turkel CC;
    Mayo Clin Proc; 2005 Sep; 80(9):1126-37. PubMed ID: 16178492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
    Suzuki K; Iizuka T; Sakai F
    Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study.
    Zidan A; Roe C; Burke D; Mejico L
    J Clin Neurosci; 2019 Nov; 69():237-240. PubMed ID: 31327585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial.
    Kaji R; Osako Y; Suyama K; Maeda T; Uechi Y; Iwasaki M;
    J Neurol; 2010 Aug; 257(8):1330-7. PubMed ID: 20358216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders.
    Blumenfeld A
    Headache; 2003 Sep; 43(8):853-60. PubMed ID: 12940806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A in post-stroke upper limb spasticity.
    Kaji R; Osako Y; Suyama K; Maeda T; Uechi Y; Iwasaki M;
    Curr Med Res Opin; 2010 Aug; 26(8):1983-92. PubMed ID: 20569068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum Toxin versus Placebo: A Meta-Analysis of Prophylactic Treatment for Migraine.
    Bruloy E; Sinna R; Grolleau JL; Bout-Roumazeilles A; Berard E; Chaput B
    Plast Reconstr Surg; 2019 Jan; 143(1):239-250. PubMed ID: 30589800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine.
    Blumenfeld AM; Schim JD; Chippendale TJ
    Headache; 2008 Feb; 48(2):210-20. PubMed ID: 18047502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
    Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-site botulinum toxin type a injection for elimination of migraine trigger points.
    Behmand RA; Tucker T; Guyuron B
    Headache; 2003; 43(10):1085-9. PubMed ID: 14629244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches.
    Relja M; Poole AC; Schoenen J; Pascual J; Lei X; Thompson C;
    Cephalalgia; 2007 Jun; 27(6):492-503. PubMed ID: 17428299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.